Events

ワークショップ「オキシトシンと自閉症」

日時:2014年329日(土)13時~17

会場:東京大学駒場Ⅰキャンパス18号館

4階コラボレーションルーム1


入場無料・事前登録不要

18号館はオートロックがかかっていますが、1245分から13時まで入館できるようにしておきます。

(それ以外の時間にいらっしゃる場合には、

事前に石原cishi08<at>mail.ecc.u-tokyo.ac.jp までご連絡ください。*<at>を@に変えてください。)


13:0013:30 棟居俊夫(金沢大学子どものこころの発達研究センター)「自閉症の社会性障害に対するオキシトシンの効果を判定する際に生ずる困難な課題~臨床試験を担当した経験に基づく一つの考察~」

l13:3014:00 高橋英之(大阪大学大学院工学研究科)「構成論的手法によるオキシトシンの作用系へのアプローチ」

14:00~14:30 北野安寿子・石原孝二(東京大学大学院総合文化研究科)「オキシトシン関連論文に見られる「社会性の障害」理解とその問題点」

15:0015:30 綾屋紗月(東京大学先端科学技術研究センター)「愛情か排他性かー出産直後をふりかえる」

15:3016:00 尾崎ミオ(東京都自閉症協会)「親のエゴについて~治療とパターナリズム」

16:0017:00 総合討論




Extended Colloquium: New Ethical Issues on Autism

 

12.03.14 (Wednesday), 13-16h

Jaspers-Bibliothek, Universitätsklinik Heidelberg

(Voss-Straße 4, Psychiatrische Universitätsklinik, Haus 1)

 

Recent years have witnessed increasing cases of early intervention in psychiatry, in dealing with mental disorders such as mood disorder or schizophrenia. In this context, oxytocin injections are gaining attention as a possible therapy for Autistic Spectrum Disorders (ASD). Relevant research results suggest that the administration of oxytocin is effective to decrease repetitive behaviors and increase socially engaging behaviors in ASD (e.g., Hollander et al., 2003). However, several ethical concerns are raised around this new therapy.

Needless to say, all the ethical questions should be asked and answered based on the precise understanding of ASD itself. This workshop mainly explores the ethical issues on the oxytocin therapy but also addresses the (re)consideration of the characteristics of ASD, such as deficits in social cognition, repetitive behaviors, and hyper-sensitivity.

 

[Program]

13:00-14:00 Elizabeth Manders (Drexel University, University of Heidelberg): “Interventions for autism and voices from the spectrum”

14:00-15:00 Urs Pohlman (Alanus University Alfter, Niklaus von Flüe Institut) and Christine Bark (Heidelberg University Hospital): “A refined diagnosis of autism as contribution to awareness of the individual”

15:00-16:00 Kohji Ishihara (The University of Tokyo): “The administration of oxytocin and the ethics of the therapy of autism”

 

Organizer: Shogo Tanaka (Tokai University, University of Heidelberg)

 

This colloquium is supported by JSPS KAKENHI (24118502) “The Neuroethics of therapy and the prevention of mental illness in adolescence and childhood” (P.I. Kohji Ishihara).


Lecture by Professor Nicolas Rose (King’s College London)

Date: 14:00-17:00 Sunday February 3, 2013
Venue: Bldg. 18, Collaboration Room 1 (4F), The University of Tokyo, Komaba I Campus

“Screen and Intervene: Governing mental disorder in the age of the biomarker”
(スクリーニングと介入:バイオマーカーの時代における精神障害の統治)
Discussants: Junko Kitanaka (Keio University) 
                      Akihito Suzuki (Keio University) 
                      Tatsuya Higaki (Osaka University)
Moderator: Kohji Ishihara (The University of Tokyo) 

Sponsored by JSPS KAKENHI (No. 24300293) ‘The neuroethics of therapy and prevention of mental illness in childhood and adolescence’
Cosponsored by Uehiro Research Division for Philosophy of Coexistence, The University of Tokyo Center for Philosophy (UTCP) and Osaka University Cross-boundary innovation program




Ethical Issues in Psychiatry Workshop

Date: 10:00-17:20 January 31, 2013
Venue:  Bldg. 18, Collaboration Room 1 (4F), The University of Tokyo, Komaba I Campus

10:00-10:50  Ryoji Sato, Koji Ota and Kohji Ishihara (The University of Tokyo)

                     Ethical issues in Neurofeedback
10:50-11:40  Kohji Ishihara (The University of Tokyo)

                     Oxytocin and Autism: Ethical Issues
13:00-13:50  Eric Racine (Institut de recherches cliniques de
Montreal (IRCM))

                     Ethics in pediatric deep brain stimulation: Are there lessons to learn?
13:50-14:40  Kevin Chien-Chang Wu (National Taiwan University)

                     Responsibilities and responsibilization in alcohol-related crimes

15:10-16:00  Toshihide Kuroki (National Organization Hospital Hizen Psychiatric Center)

                     A dramatic increase in the use of psychotropic drugs in children and

                      adolescents: Current status in the United States and Japan

16:00-16:50  Masafumi Mizuno (Toho University)

                     Ethics of early intervention for early psychosis
16:50-17:20  Closing


lecture 

Mind over Matter: Placebo for Psychogenic Movement Disorders(心因性運動障害に対するプラシーボ治療)

KAREN S. ROMMELFANGER, PH.D. (Emory University)
  Neuroethics Program Director, Center for Ethics/ Fellow, Scholars Program
  in Interdisciplinary Neuroscience Research, Department of Neurology

16:00-18:00, September 24, 2012
Venue: Meeting room 4F, JST TOKYO Head Quarter 2nd (K's Gobancho)7 Gobancho
Chiyoda-ku, Tokyo 102-0076 JAPAN(JST東京本部別館、K’s五番町ビル、4F 会議室)
Admission Free
Regisitration required (要参加登録): cishi08<at>mail.ecc.u-tokyo.ac.jp (Kohji Ishihara)
Moderator: Tamami Fukushi, Ph.D. (JST)
 

Abstract

Psychogenic movement disorders (PMD) mimic known movement disorders, yet cannot be attributed to an underlying neurological substrate. PMD has been reported to affect up to 15-25% of patients who visit specialized movement disorder clinics. The lack of mechanistic understanding of this disorder contributes to the hesitation of physicians to give a diagnosis of PMD, and patients often experience inordinate healthcare costs and multiple referrals between psychiatrists and neurologists who have differing views on the diagnosis and terminology of PMD. Given that the prognosis for PMD is poor, that the success of standard treatment for PMD is highly dependent on the patient’s belief in the diagnosis and treatment regimen, and that case studies suggest the efficacy of placebo for PMD, placebo therapy has recently been advocated for PMD. Recent surveys report a high percentage of physicians administering placebo therapy. Therefore, perhaps, the ethical question in PMD should be, “Are we harming patients by withholding placebo treatment?”

PMD and placebo share, and perhaps suffer from, the same dualistic mind-body conceptualization wherein a psychological origin or nature (e.g. the mind) is not physiologically based and is somehow separate from the body (e.g. the brain). However, neuroscience research has begun to establish physiological evidence of placebo activity, which challenges notions that placebos are truly inert, and thereby challenges the bioethical claims against placebo therapy. While placebo therapy may not be ideal for all diseases, placebo therapy becomes more defensible for diseases that lack successful standard measures of care. PMD patients are thus, promising candidates for placebo therapy. Effects of placebo can be physiologically potent; however, substantial empirical evidence demonstrates that placebo effects are highly contextually dependent on clinical environment and physician attitudes.  In this neuroethics discussion, we will explore the neurobiology of psychogenic movement disorders and placebo as well as the ethical issues around current contexts of care for PMD patients. 

 

Sponsored by JSPS Grant-in-Aid for Scientific Research (24118502) P.I. Kohji Ishihara

Ċ
Kohji Ishihara,
2013/01/08 4:18
Ċ
Kohji Ishihara,
2013/01/08 4:22
Ċ
Kohji Ishihara,
2014/03/12 3:21
Ċ
Kohji Ishihara,
2012/09/05 19:23
Ċ
Kohji Ishihara,
2014/03/12 22:46
Comments